Clinical Trial Update: Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating IPI-549 in combination with nivolumab for advanced urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cancer
• Solid Tumor
• Urothelial Carcinoma

Drugs mentioned

• IPI-549
• nivolumab (nivolumab)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Bladder Cancer, Urothelial Carcinoma | Phase 2 | Status: COMPLETED